Your browser doesn't support javascript.
loading
Time Interval Between the End of Neoadjuvant Therapy and Elective Resection of Locally Advanced Rectal Cancer in the CRONOS Study.
Guzmán, Yoelimar; Ríos, José; Paredes, Jesús; Domínguez, Paula; Maurel, Joan; González-Abós, Carolina; Otero-Piñeiro, Ana; Almenara, Raúl; Ladra, María; Prada, Borja; Pascual, Marta; Guerrero, María Alejandra; García-Granero, Álvaro; Fernández, Laura; Ochogavia-Seguí, Aina; Gamundi-Cuesta, Margarita; González-Argente, Francesc Xavier; Pons, Lorenzo Viso; Centeno, Ana; Arrayás, Ángela; de Miguel, Andrea; Gil-Gómez, Elena; Gómez, Beatriz; Martínez, José Gil; Lacy, Antonio M; de Lacy, F Borja.
Affiliation
  • Guzmán Y; Department of Gastrointestinal Surgery, Institute of Digestive and Metabolic Diseases, Hospital Clinic of Barcelona, University of Barcelona, Catalonia, Spain.
  • Ríos J; Department of Clinical Farmacology, Hospital Clinic and Medical Statistics Core Facility, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Paredes J; Biostatistics Unit, Faculty of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Domínguez P; General and Digestive Surgery Department, Colorectal Surgery Unit, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Galicia, Spain.
  • Maurel J; Department of Gastrointestinal Surgery, Institute of Digestive and Metabolic Diseases, Hospital Clinic of Barcelona, University of Barcelona, Catalonia, Spain.
  • González-Abós C; Medical Oncology Departments, Hospital Clínic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, University of Barcelona, Barcelona, Catalonia, Spain.
  • Otero-Piñeiro A; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain.
  • Almenara R; Department of Gastrointestinal Surgery, Institute of Digestive and Metabolic Diseases, Hospital Clinic of Barcelona, University of Barcelona, Catalonia, Spain.
  • Ladra M; Department of Gastrointestinal Surgery, Institute of Digestive and Metabolic Diseases, Hospital Clinic of Barcelona, University of Barcelona, Catalonia, Spain.
  • Prada B; Department of Gastrointestinal Surgery, Institute of Digestive and Metabolic Diseases, Hospital Clinic of Barcelona, University of Barcelona, Catalonia, Spain.
  • Pascual M; General and Digestive Surgery Department, Colorectal Surgery Unit, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Galicia, Spain.
  • Guerrero MA; General and Digestive Surgery Department, Colorectal Surgery Unit, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Galicia, Spain.
  • García-Granero Á; General Surgery Department, Section of Colon and Rectal Surgery Unit, Hospital del Mar, Barcelona, Catalonia, Spain.
  • Fernández L; General Surgery Department, Section of Colon and Rectal Surgery Unit, Hospital del Mar, Barcelona, Catalonia, Spain.
  • Ochogavia-Seguí A; Coloproctology Unit, Health Research Institute of the Balearic Islands, 3D-Reconstruction Unit and Simulation Center, Hospital Universitario Son Espases, Professor of Human Embriology and Anatomy Department, University of Islas Baleares, Palma de Mallorca, Spain.
  • Gamundi-Cuesta M; Coloproctology Unit, Hospital Universitario Son Espases, Palma de Mallorca, Spain.
  • González-Argente FX; Coloproctology Unit, Hospital Universitario Son Espases, Palma de Mallorca, Spain.
  • Pons LV; Coloproctology Unit, Hospital Universitario Son Espases, Palma de Mallorca, Spain.
  • Centeno A; Coloproctology Unit, Hospital Universitario Son Espases, Palma de Mallorca, Spain.
  • Arrayás Á; General and Digestive Surgery Department, Colorectal Surgery Unit, Consorci Sanitari Integral - Hospital General de l'Hospitalet, Barcelona, Catalonia, Spain.
  • de Miguel A; General and Digestive Surgery Department, Colorectal Surgery Unit, Consorci Sanitari Integral - Hospital General de l'Hospitalet, Barcelona, Catalonia, Spain.
  • Gil-Gómez E; General and Digestive Surgery Department, Colorectal Surgery Unit, Consorci Sanitari Integral - Hospital General de l'Hospitalet, Barcelona, Catalonia, Spain.
  • Gómez B; General and Digestive Surgery Department, Colorectal Surgery Unit, Consorci Sanitari Integral - Hospital General de l'Hospitalet, Barcelona, Catalonia, Spain.
  • Martínez JG; General and Digestive Surgery Department, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
  • Lacy AM; General and Digestive Surgery Department, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
  • de Lacy FB; General and Digestive Surgery Department, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
JAMA Surg ; 158(9): 910-919, 2023 09 01.
Article in En | MEDLINE | ID: mdl-37436726
ABSTRACT
Importance The treatment for extraperitoneal locally advanced rectal cancer (LARC) is neoadjuvant therapy (NAT) followed by total mesorectal excision (TME). Robust evidence on the optimal time interval between NAT completion and surgery is lacking.

Objective:

To assess the association of time interval between NAT completion and TME with short- and long-term outcomes. It was hypothesized that longer intervals increase the pathologic complete response (pCR) rate without increasing perioperative morbidity. Design, Setting, and

Participants:

This cohort study included patients with LARC from 6 referral centers who completed NAT and underwent TME between January 2005 and December 2020. The cohort was divided into 3 groups depending on the time interval between NAT completion and surgery short (≤8 weeks), intermediate (>8 and ≤12 weeks), and long (>12 weeks). The median follow-up duration was 33 months. Data analyses were conducted from May 1, 2021, to May 31, 2022. The inverse probability of treatment weighting method was used to homogenize the analysis groups. Exposure Long-course chemoradiotherapy or short-course radiotherapy with delayed surgery. Main outcome and

Measures:

The primary outcome was pCR. Other histopathologic results, perioperative events, and survival outcomes constituted the secondary outcomes.

Results:

Among the 1506 patients, 908 were male (60.3%), and the median (IQR) age was 68.8 (59.4-76.5) years. The short-, intermediate-, and long-interval groups included 511 patients (33.9%), 797 patients (52.9%), and 198 patients (13.1%), respectively. The overall pCR was 17.2% (259 of 1506 patients; 95% CI, 15.4%-19.2%). When compared with the intermediate-interval group, no association was observed between time intervals and pCR in short-interval (odds ratio [OR], 0.74; 95% CI, 0.55-1.01) and long-interval (OR, 1.07; 95% CI, 0.73-1.61) groups. The long-interval group was significantly associated with lower risk of bad response (tumor regression grade [TRG] 2-3; OR, 0.47; 95% CI, 0.24-0.91), systemic recurrence (hazard ratio, 0.59; 95% CI, 0.36-0.96), higher conversion risk (OR, 3.14; 95% CI, 1.62-6.07), minor postoperative complications (OR, 1.43; 95% CI, 1.04-1.97), and incomplete mesorectum (OR, 1.89; 95% CI, 1.02-3.50) when compared with the intermediate-interval group. Conclusions and Relevance Time intervals longer than 12 weeks were associated with improved TRG and systemic recurrence but may increase surgical complexity and minor morbidity.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rectal Neoplasms / Neoadjuvant Therapy Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Female / Humans / Male Language: En Journal: JAMA Surg Year: 2023 Document type: Article Affiliation country: Spain

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rectal Neoplasms / Neoadjuvant Therapy Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Female / Humans / Male Language: En Journal: JAMA Surg Year: 2023 Document type: Article Affiliation country: Spain